Monday, June 30, 2025 6/30/2025

The Boston Lung Cancer Survival Cohort

Award Number: U01CA209414
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2017
PERIOD OF PERFORMANCE END DATE: 05/31/2028

Group Awards By:

View Award Description

The Boston Lung Cancer Survival Cohort - The Boston Lung Cancer Survival (BLCS) cohort is a Cancer Epidemiology Cohort of more than 12,000 lung cancer cases enrolled at Massachusetts General Hospital and the Dana-Farber Cancer Institute since 1992. This rich resource enables research to understand lung cancer heterogeneity that has already identified valuable prognostic markers and stimulated new treatment strategies. For example, the BLCS supported the first discovery of the association between EGFR mutations and response to therapy with EGFR-tyrosine kinase inhibitors and enabled research on effective treatments for non-small cell lung cancer patients with ALK and ROS1 rearrangements. In 2017, the cohort evolved into a survivor epidemiology cohort that is sustained by a U01 grant until May 2023. Our progress during the first U01 funding cycle (2017–2022) is substantial—we have published over 100 papers, supported 6 new grants, and worked with 50 collaborators nationally and internationally. With the U01 award expiring soon, there is an urgency to renew to: 1) maintain this first and most comprehensive lung cancer survivor cohort with the longest follow-up period—an unmatched source of data for translational research; 2) establish an innovative, detailed phenotyping database via automated image analysis of high-resolution computed tomography, as well as a radiomics database; 3) enable the established infrastructure to facilitate internal and external investigators to pilot methodologic approaches that will turn into productive multidisciplinary project grants by focusing on survival and treatment toxicity; and 4) leverage the Dana-Farber/Harvard Cancer Center Lung Program resources for creative multidisciplinary collaborations focused on treatment outcomes. Renewed funding is also critical to recruit 2,500 new cases (for a total of 14,500 cases) to this already large cohort. New cases are vitally important to: 1) facilitate comparison of new treatments and traditional therapy as well as evaluation of new clinical investigation in an ever-changing therapeutic environment; 2) allow us to collect more cases with driver mutation data, as well as those treated with immune checkpoint inhibitors; 3) promote collection of repeated biological samples to support developing prognostic/predictive biomarkers; 4) allow us to collect detailed data enabling assessment of environmental determinants as well as racial and socioeconomic determinants of survival; and 5) empower our studies to identify radiomic, genomic, epigenetic, and other phenomic biomarkers, environmental determinants, and racial and socioeconomic determinants that are relevant to patient survival to guide improved lung cancer screening and treatment strategies. The BLCS is one of the largest lung cancer survival cohorts and encompasses a wealth of biomarker, tumor molecular characterization, imaging, lung function, genetic, epigenetic, traditional epidemiologic risk factor, and electronic health record data. With continued support, this comprehensive cohort will provide unique opportunities to explore predictors of lung cancer survival and treatment outcomes, catalyzing powerful translational research that improves the health of individuals with lung cancer.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $1,043,892 )
2025	2025	HARVARD COLLEGE PRESIDENT & FELLOWS OF	677 HUNTINGTON AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Cause and Prevention Research	001	9	4/11/2025	NON-COMPETING CONTINUATION	$1,043,892
2025	2024	HARVARD COLLEGE PRESIDENT & FELLOWS OF	677 HUNTINGTON AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Cause and Prevention Research	000	8	10/23/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $1,043,892

Issue Date FY: 2024 ( Subtotal = $1,113,227 )
2024	2024	HARVARD COLLEGE PRESIDENT & FELLOWS OF	677 HUNTINGTON AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Cause and Prevention Research	003	8	5/23/2024	NON-COMPETING CONTINUATION	$1,113,227
2024	2023	HARVARD COLLEGE PRESIDENT & FELLOWS OF	677 HUNTINGTON AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Cause and Prevention Research	000	7	11/22/2023	COMPETING CONTINUATION	$0
2024	2023	HARVARD COLLEGE PRESIDENT & FELLOWS OF	677 HUNTINGTON AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Cause and Prevention Research	002	7	5/22/2024	COMPETING CONTINUATION	$75,108
2024	2022	HARVARD COLLEGE PRESIDENT & FELLOWS OF	677 HUNTINGTON AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Cause and Prevention Research	001	6	5/22/2024	NON-COMPETING CONTINUATION	-$75,108
														Subtotal = $1,113,227

Issue Date FY: 2023 ( Subtotal = $1,231,212 )
2023	2023	HARVARD COLLEGE PRESIDENT & FELLOWS OF	677 HUNTINGTON AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Cause and Prevention Research	001	7	4/20/2023	COMPETING CONTINUATION	$1,231,212
2023	2022	HARVARD COLLEGE PRESIDENT & FELLOWS OF	677 HUNTINGTON AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Cause and Prevention Research	000	6	3/2/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $1,231,212

Issue Date FY: 2022 ( Subtotal = $1,253,492 )
2022	2022	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	677 HUNTINGTON AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Cause and Prevention Research	001	6	5/27/2022	NON-COMPETING CONTINUATION	$1,253,492
2022	2021	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	677 HUNTINGTON AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Cause and Prevention Research	000	5	3/4/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $1,253,492

Issue Date FY: 2021 ( Subtotal = $1,275,710 )
2021	2021	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	677 HUNTINGTON AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Cause and Prevention Research	001	5	6/1/2021	NON-COMPETING CONTINUATION	$1,275,710
2021	2020	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	677 HUNTINGTON AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Cause and Prevention Research	000	4	2/16/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $1,275,710

Issue Date FY: 2020 ( Subtotal = $1,366,752 )
2020	2020	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	677 HUNTINGTON AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Cause and Prevention Research	000	4	5/20/2020	NON-COMPETING CONTINUATION	$1,237,929
2020	2020	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	677 HUNTINGTON AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Cause and Prevention Research	001	4	8/24/2020	NON-COMPETING CONTINUATION	$128,823
														Subtotal = $1,366,752

Issue Date FY: 2019 ( Subtotal = $339,710 )
2019	2019	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	677 HUNTINGTON AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Cause and Prevention Research	000	3	5/30/2019	NON-COMPETING CONTINUATION	$339,710
														Subtotal = $339,710

Issue Date FY: 2018 ( Subtotal = $1,626,509 )
2018	2018	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	677 HUNTINGTON AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Cause and Prevention Research	000	2	7/3/2018	NON-COMPETING CONTINUATION	$1,626,509
														Subtotal = $1,626,509

Issue Date FY: 2017 ( Subtotal = $1,694,687 )
2017	2017	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	677 HUNTINGTON AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Cause and Prevention Research	000	1	5/31/2017	NEW	$1,660,018
2017	2017	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	677 HUNTINGTON AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Cause and Prevention Research	001	1	9/25/2017	NEW	$34,669
														Subtotal = $1,694,687

Grand Total All Awards = $10,945,191

Top

All Categories

About

Search

Reports

Data Submission

Award Information

The Boston Lung Cancer Survival Cohort

Award Number: U01CA209414

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2017

PERIOD OF PERFORMANCE END DATE: 05/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer